News 2018

MedAlliance Raises $37 Million to Launch Sirolimus Drug-Coated Balloon

M.A. MedAlliance SA, a company developing and commercializing the first sirolimus micro-reservoir drug-coated balloon (SELUTION™ DCB) to treat patients suffering from peripheral artery disease (PAD), coronary artery disease (CAD), arteriovenous fistulas (AVF) and grafts (AVG) for end-stage renal disease, has raised $37 million.

read more

SELUTION™ First-in-Man Study Achieves Primary Endpoint

Primary endpoint data from the First-in-Man (FIM) study of SELUTION™, Med Alliance’s novel sirolimus-coated balloon, was presented today at the Leipzig Interventional Course (LINC) by Principal Investigator Professor Thomas Zeller, Universitaets-Herzzentrum, Bad Krozingen, Germany.

read more

Med Alliance Announces Strategic Agreement with Kaneka Corporation

Swiss-based medical technology company Med Alliance has announced a strategic agreement with Kaneka Corporation, Japan’s leading provider of PTCA balloons. The agreement involves technical collaboration, product licensing, manufacturing and distribution for the Med Alliance sirolimus Drug-Coated Balloon (DCB) in Japan for the treatment of coronary arteries.

read more